Literature DB >> 2207292

Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate.

G Würthwein1, P Rohdewald.   

Abstract

The relative affinity of beclomethasone (B), beclomethasone-17-monopropionate (17-BMP), beclomethasone-21-monopropionate (21-BMP), and beclomethasone dipropionate (BDP) has been determined. BDP binds to the glucocorticoid receptor with about half the affinity of the potent glucocorticoid dexamethasone (Dexa), B was found to be 0.75 times less active than Dexa. The 21-BMP has no binding affinity whereas the 17-BMP is about 13 times as potent as Dexa. The affinity data indicate that metabolism of BDP to 17-BMP is an important activation step. To evaluate the relationship between local and systemic activity incubation studies with BDP in human lung, simulated gastric and intestinal fluid and plasma were performed. In cytosol from human lung cells BDP is hydrolysed rapidly to the more stable 17-BMP. During gastric passage BDP is stable but is immediately hydrolysed to 17-BMP in intestinal fluid. In human plasma BDP is hydrolysed to 17-BMP and an interesterification of 17-BMP to the inactive 21-BMP was also found.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2207292     DOI: 10.1002/bdd.2510110503

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  19 in total

1.  Metabolism kinetics of beclomethasone propionate esters in human lung homogenates.

Authors:  K Foe; D J Cutler; K F Brown; J P Seale
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

2.  Inhaled corticosteroids: benefits and risks.

Authors:  B J Smith
Journal:  Thorax       Date:  1992-12       Impact factor: 9.139

3.  Influence of oral beclomethasone dipropionate on early non-infectious pulmonary outcomes after allogeneic hematopoietic cell transplantation: results from two randomized trials.

Authors:  J W Chien; M Sakai; T A Gooley; H G Schoch; G B McDonald
Journal:  Bone Marrow Transplant       Date:  2009-06-29       Impact factor: 5.483

4.  Urinary pharmacokinetic methodology to determine the relative lung bioavailability of inhaled beclometasone dipropionate.

Authors:  Amira S A Said; Lindsay P Harding; Henry Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

5.  Adrenal axis suppression unrelated to the dynamics of dosing with beclomethasone monopropionate.

Authors:  Siobhan A Mulrennan; Joseph S Hogg; Richard C Teoh; Alyn H Morice
Journal:  Br J Clin Pharmacol       Date:  2006-09-19       Impact factor: 4.335

6.  Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man.

Authors:  P T Daley-Yates; A C Price; J R Sisson; A Pereira; N Dallow
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

7.  Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone.

Authors:  Sarita D Boyd; Colleen Hadigan; Maryellen McManus; Cheryl Chairez; Lynnette K Nieman; Alice K Pau; Raul M Alfaro; Joseph A Kovacs; Monica M Calderon; Scott R Penzak
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07-01       Impact factor: 3.731

Review 8.  Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept.

Authors:  M Schäfer-Korting; M H Schmid; H C Korting
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

9.  Effect of orally administered beclomethasone dipropionate on calcium absorption from the gut in normal subjects.

Authors:  B J Smith; P J Phillips; P R Pannall; H J Cain; W J Leckie
Journal:  Thorax       Date:  1993-09       Impact factor: 9.139

10.  The gastrointestinal passage and release of beclomethasone dipropionate from oral delivery systems in ileostomy volunteers.

Authors:  J Burggraaf; A D van Haarst; P Fockens; H C Schoemaker; W J Krauwinkel; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.